Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radio-Marker: Biomarkers of 177Lu-DOTATATE Response in NET
NCT05513469Unknown
- Sponsor
- Erasmus MC
- Start
- Jan 2023
- Primary completion
- Oct 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lutetium Lu 177 dotatate in Midgut neuroendocrine tumor, sponsored by Erasmus MC. Primary endpoint: Transcriptional regulation and DNA damage induction in PBMCs after PRRT at 2 years. Status: unknown.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Midgut neuroendocrine tumor
Beyond the preview
Go deeper on NCT05513469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05513469.